Before anything else
Moderna’s filed revenue has fallen every year since 2022, and the company is burning through roughly $600 million a quarter. The stock, at $150.81, prices the business at 28 times what it actually sold in the past year, a multiple our data places at the 99th percentile of Moderna’s own history. One Phase 3 cancer-vaccine result announced in August 2026 drove most of that valuation. The open question is whether a single trial outcome, in a disease where regulatory approval is still months away, justifies a price tag that assumes a business transformation the filings have not yet begun to show.
From pandemic windfall to a company rebuilding from scratch
Moderna went public in December 2018 at $23 a share, a biotech with a promising technology and no approved product. Two years later, the FDA granted emergency authorization for its COVID-19 vaccine, and the company’s finances were transformed overnight. By 2021, revenue hit $18.5 billion, and net margins ran above 66%. Revenue edged higher still in 2022, reaching $19.3 billion, before the collapse began. What followed was one of the steepest revenue collapses in recent corporate history: three straight years of decline, each worse than the last.
By the full year 2025, revenue had fallen to roughly a tenth of the 2021 figure. The company that once earned more in a quarter than most biotechs earn in a decade was posting operating losses and cutting staff. A workforce reduction landed by July 2025, and a major CMV vaccine program was discontinued in October 2025 after failing its primary endpoint. The math of the business, meaning what the filed numbers actually show, tells a story of a company still searching for its second act.
Then came August 19, 2026.
The trial that moved the price tag by $44 billion in a day
On that date, Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine, mRNA-4157/V940, combined with Merck’s cancer drug Keytruda, in patients with advanced melanoma. The combination showed statistically significant improvements in how long patients stayed free of recurrence compared to Keytruda alone. Merck Research Laboratories president Dr. Dean Li said patients “have a better chance of being disease-free, and for longer.” The stock surged 177% in a single session, adding roughly $44 billion to Moderna’s market value, more than the company earned across its entire peak year of COVID profits.
That reaction is the mood, meaning what the market is currently willing to pay based on sentiment and expectations. The math, meaning what the filed fundamentals actually support today, looks quite different. The cancer vaccine has not been submitted for regulatory approval yet. A filing, a review, and a commercial launch each take time. What the market priced in on August 19 was a future that the filings cannot yet confirm.
A household analogy helps here. Imagine a family that earns a strong income at their peak, then watches it fall to a tenth of that over four years. A neighbor offers to pay nearly thirty times their current annual earnings for their house, not because of what they earn now, but because they heard the family might land a transformative new job. That is roughly the proportional bet embedded in Moderna’s current valuation.
What the quarterly filings actually show right now
The Q2 2026 10-Q filed for the quarter ended June 30, 2026, reported total revenue of $145 million for the quarter, against R&D expenses of $651 million. To put that in scale: Moderna spent more on research in one quarter than it earned in revenue across several quarters at the current run rate. That is not a criticism of the strategy; heavy R&D spending before a product launch is how drug development works. But it is the reality the math reflects.
Cash is the runway that keeps the strategy alive. As of June 30, 2026, Moderna held $6.9 billion in cash and investments. After a substantial litigation settlement paid in July 2026, the company forecasts year-end 2026 cash of $4.7 billion to $5.2 billion. At the current burn rate, that is somewhere between seven and nine quarters of runway before the company would need to raise new money or reach breakeven. Management has set cash-flow breakeven as a 2028 target.
The good news on costs: R&D spending fell meaningfully year-over-year in Q2 2026, and the full-year budget has been trimmed, down from the prior year. The company is tightening the belt while it waits for new products to generate revenue.
Three products, one big bet, and a setback already in the data
Moderna’s path to breakeven rests on launching up to three new products by 2027 to 2028: a flu-plus-COVID combination vaccine, a standalone seasonal flu vaccine (mFlusvia), and a norovirus vaccine. The RSV vaccine mRESVIA received FDA approval in August 2026 for adults at elevated risk who are younger than the original approval covered, adding to its existing authorization. These are real regulatory wins.
But the norovirus vaccine stumbled. The Phase 3 trial did not meet early success criteria at its interim analysis, a setback that removes one of the nearer-term revenue pillars. And on the flu side, MarketScreener noted that GSK’s own mRNA flu program is advancing, meaning Moderna will not have the seasonal flu market to itself. Analyst forecasts put mFlusvia’s eventual sales well short of the revenue needed to justify the current valuation on their own, and those revenues arrive years from now.
The cancer vaccine is the biggest bet. If mRNA-4157/V940 wins regulatory approval and reaches commercial scale, the addressable market across multiple cancer types could be enormous. But “could be” is doing heavy lifting in a sentence about a product that has not yet been filed with any regulator. Sell-side consensus valuations as of September 1, 2026 averaged $80.53, according to The Motley Fool, roughly half the current price. That roughly $70-per-share gap between where external analysts’ arithmetic lands and where the tape sits illustrates the scale of the forward assumptions currently embedded in the price.
Reading the numbers
- Revenue: $145 million (Q2 2026, filed). This is what Moderna actually sold in the three months ended June 30, 2026. For context, the company’s quarterly R&D bill alone is more than four times that figure. A household earning $1,000 a month but spending $4,500 on education and training is betting heavily that the degree pays off.
- Price-to-sales ratio: 28.3 (our data, computed against trailing revenue). This is the price tag per dollar of annual sales. The S&P 500 as a whole trades near 3.3 times sales. Moderna’s ratio means the market is paying about eight times the broad-market premium for each dollar Moderna earns. The 99th percentile of Moderna’s own history means the stock has almost never been priced this richly relative to its own revenue record.
- Cash runway: $4.7 billion to $5.2 billion forecast at year-end 2026 (management guidance, Q2 2026 earnings call). At $600 million of quarterly burn, that is roughly two years of operating capacity before the company would need to raise capital or reach breakeven. If the cancer vaccine regulatory process runs longer than expected, that runway matters a great deal.
- R&D expense: $651 million in Q2 2026, down 7% year-over-year (filed). Cutting R&D is a double-edged signal: it shows discipline on costs, but it also means fewer shots on goal. Moderna is concentrating its bets rather than spreading them, which raises the stakes on the programs that remain.
- Consensus valuation estimate: $80.53 average (as of September 1, 2026, via The Motley Fool). The stock trades at $150.81. The roughly $70-per-share spread between external analyst arithmetic and the current tape reflects the magnitude of forward assumptions, chiefly around cancer-vaccine approval timing and commercial scale, that the filed financials do not yet corroborate.
For the standing yardsticks on Moderna: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Moderna.
Sources
- Moderna 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Moderna 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Moderna 10-K, fiscal year ended December 31, 2023 (SEC EDGAR)
- Moderna Q2 2026 earnings release (StockTitan)
- Merck and Moderna Phase 3 cancer vaccine results (FierceBiotech)
- mRESVIA FDA approval (FDA.gov)
- Moderna valuation and competitive commentary (MarketScreener)
- Moderna analyst consensus and valuation estimates (The Motley Fool, September 1, 2026)
- Moderna cash burn and cost-cut detail (Investing.com)
